Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 404

1.

Functional Profiling of Chondrogenically Induced Multipotent Stromal Cell Aggregates Reveals Transcriptomic and Emergent Morphological Phenotypes Predictive of Differentiation Capacity.

Lam J, Bellayr IH, Marklein RA, Bauer SR, Puri RK, Sung KE.

Stem Cells Transl Med. 2018 Sep;7(9):664-675. doi: 10.1002/sctm.18-0065. Epub 2018 Aug 7.

3.

Recommended standards for conducting and reporting ethnopharmacological field studies.

Weckerle CS, de Boer HJ, Puri RK, van Andel T, Bussmann RW, Leonti M.

J Ethnopharmacol. 2018 Jan 10;210:125-132. doi: 10.1016/j.jep.2017.08.018. Epub 2017 Aug 20.

PMID:
28834697
4.

MicroRNA expression in bone marrow-derived human multipotent Stromal cells.

Bellayr IH, Kumar A, Puri RK.

BMC Genomics. 2017 Aug 11;18(1):605. doi: 10.1186/s12864-017-3997-7.

5.

Differential host gene responses from infection with neurovirulent and partially-neurovirulent strains of Venezuelan equine encephalitis virus.

Gupta P, Sharma A, Han J, Yang A, Bhomia M, Knollmann-Ritschel B, Puri RK, Maheshwari RK.

BMC Infect Dis. 2017 Apr 26;17(1):309. doi: 10.1186/s12879-017-2355-3.

6.

Current Status and Challenges of Three-Dimensional Modeling and Printing of Tissues and Organs.

Husain SR, Ohya Y, Puri RK.

Tissue Eng Part A. 2017 Jun;23(11-12):471-473. doi: 10.1089/ten.tea.2017.29000.srh. Epub 2017 Feb 16. No abstract available.

PMID:
28437213
7.

Treating infants with frigg: linking disease aetiologies, medicinal plant use and care-seeking behaviour in southern Morocco.

Teixidor-Toneu I, Martin GJ, Puri RK, Ouhammou A, Hawkins JA.

J Ethnobiol Ethnomed. 2017 Jan 13;13(1):4. doi: 10.1186/s13002-016-0129-4.

8.

Comprehensive dataset of the medicinal plants used by a Tashelhit speaking community in the High Atlas, Morocco.

Teixidor-Toneu I, Martin GJ, Ouhammou A, Puri RK, Hawkins JA.

Data Brief. 2016 Jun 7;8:516-9. doi: 10.1016/j.dib.2016.05.079. eCollection 2016 Sep.

9.

An ethnomedicinal survey of a Tashelhit-speaking community in the High Atlas, Morocco.

Teixidor-Toneu I, Martin GJ, Ouhammou A, Puri RK, Hawkins JA.

J Ethnopharmacol. 2016 Jul 21;188:96-110. doi: 10.1016/j.jep.2016.05.009. Epub 2016 May 10.

PMID:
27174082
10.

Identification of Predictive Gene Markers for Multipotent Stromal Cell Proliferation.

Bellayr IH, Marklein RA, Lo Surdo JL, Bauer SR, Puri RK.

Stem Cells Dev. 2016 Jun 1;25(11):861-73. doi: 10.1089/scd.2015.0374. Epub 2016 May 2.

PMID:
27036644
11.

High Content Imaging of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human Mesenchymal Stem Cells upon Osteogenic Induction.

Marklein RA, Lo Surdo JL, Bellayr IH, Godil SA, Puri RK, Bauer SR.

Stem Cells. 2016 Apr;34(4):935-47. doi: 10.1002/stem.2322. Epub 2016 Feb 29.

12.

Foodways in transition: food plants, diet and local perceptions of change in a Costa Rican Ngäbe community.

D'Ambrosio U, Puri RK.

J Ethnobiol Ethnomed. 2016 Jan 6;12:3. doi: 10.1186/s13002-015-0071-x.

13.

Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.

Joshi BH, Suzuki A, Fujisawa T, Leland P, Varrichio F, Lababidi S, Lloyd R, Kasperbauer J, Puri RK.

Discov Med. 2015 Nov;20(111):273-84.

14.

Gene therapy for cancer: regulatory considerations for approval.

Husain SR, Han J, Au P, Shannon K, Puri RK.

Cancer Gene Ther. 2015 Dec;22(12):554-63. doi: 10.1038/cgt.2015.58. Epub 2015 Nov 20. Review.

15.

Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.

Čokić VP, Mojsilović S, Jauković A, Kraguljac-Kurtović N, Mojsilović S, Šefer D, Mitrović Ajtić O, Milošević V, Bogdanović A, Đikić D, Milenković P, Puri RK.

Blood Cells Mol Dis. 2015 Dec;55(4):373-81. doi: 10.1016/j.bcmd.2015.08.002. Epub 2015 Aug 7.

16.

Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway.

Čokić VP, Mossuz P, Han J, Socoro N, Beleslin-Čokić BB, Mitrović O, Subotički T, Diklić M, Leković D, Gotić M, Puri RK, Noguchi CT, Schechter AN.

PLoS One. 2015 Aug 14;10(8):e0135463. doi: 10.1371/journal.pone.0135463. eCollection 2015.

17.

Targeting of IL-4 and IL-13 receptors for cancer therapy.

Suzuki A, Leland P, Joshi BH, Puri RK.

Cytokine. 2015 Sep;75(1):79-88. doi: 10.1016/j.cyto.2015.05.026. Epub 2015 Jun 15. Review.

PMID:
26088753
18.

Phase I trial of systemic intravenous infusion of interleukin-13-Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma.

Liu-Chittenden Y, Jain M, Kumar P, Patel D, Aufforth R, Neychev V, Sadowski S, Gara SK, Joshi BH, Cottle-Delisle C, Merkel R, Yang L, Miettinen M, Puri RK, Kebebew E.

Cancer Med. 2015 Jul;4(7):1060-8. doi: 10.1002/cam4.449. Epub 2015 Mar 13.

19.

Design and development of an in-line sputtering system and process development of thin film multilayer neutron supermirrors.

Biswas A, Sampathkumar R, Kumar A, Bhattacharyya D, Sahoo NK, Lagoo KD, Veerapur RD, Padmanabhan M, Puri RK, Bhattacharya D, Singh S, Basu S.

Rev Sci Instrum. 2014 Dec;85(12):123103. doi: 10.1063/1.4902184.

PMID:
25554268
20.

Regulation of biologic oncology products in the FDA׳s Center for Biologics Evaluation and Research.

Bross PF, Fan C, George B, Shannon K, Joshi BH, Puri RK.

Urol Oncol. 2015 Mar;33(3):133-6. doi: 10.1016/j.urolonc.2014.10.016. Epub 2014 Oct 30. Review.

PMID:
25441459
21.

Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease.

Joshi BH, Leland P, Lababidi S, Varrichio F, Puri RK.

Cancer Med. 2014 Dec;3(6):1615-28. doi: 10.1002/cam4.330. Epub 2014 Sep 10.

22.

Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma.

Suzuki A, Leland P, Kobayashi H, Choyke PL, Jagoda EM, Inoue T, Joshi BH, Puri RK.

J Nucl Med. 2014 Aug;55(8):1323-9. doi: 10.2967/jnumed.114.138404. Epub 2014 Jun 19.

23.

Gene markers of cellular aging in human multipotent stromal cells in culture.

Bellayr IH, Catalano JG, Lababidi S, Yang AX, Lo Surdo JL, Bauer SR, Puri RK.

Stem Cell Res Ther. 2014 Apr 28;5(2):59. doi: 10.1186/scrt448.

24.

Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma.

Han J, Fujisawa T, Husain SR, Puri RK.

BMC Cancer. 2014 Mar 11;14:173. doi: 10.1186/1471-2407-14-173.

25.

Current status of multipotent mesenchymal stromal cells.

Husain SR, Ohya Y, Toguchida J, Puri RK.

Tissue Eng Part B Rev. 2014 Jun;20(3):189. doi: 10.1089/ten.TEB.2014.0105. Epub 2014 Mar 31. No abstract available.

26.

IL-13Rα2-bearing, type II NKT cells reactive to sulfatide self-antigen populate the mucosa of ulcerative colitis.

Fuss IJ, Joshi B, Yang Z, Degheidy H, Fichtner-Feigl S, de Souza H, Rieder F, Scaldaferri F, Schirbel A, Scarpa M, West G, Yi C, Xu L, Leland P, Yao M, Mannon P, Puri RK, Fiocchi C, Strober W.

Gut. 2014 Nov;63(11):1728-36. doi: 10.1136/gutjnl-2013-305671. Epub 2014 Feb 10.

27.

MSC-based product characterization for clinical trials: an FDA perspective.

Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR.

Cell Stem Cell. 2014 Feb 6;14(2):141-5. doi: 10.1016/j.stem.2014.01.013.

28.

Molecular characterization of antigen-peptide pulsed dendritic cells: immature dendritic cells develop a distinct molecular profile when pulsed with antigen peptide.

Yang AX, Chong N, Jiang Y, Catalano J, Puri RK, Khleif SN.

PLoS One. 2014 Jan 27;9(1):e86306. doi: 10.1371/journal.pone.0086306. eCollection 2014.

29.

IL-13 immunotoxin accelerates resolution of lung pathological changes triggered by silica particles in mice.

Ferreira TP, de Arantes AC, do Nascimento CV, Olsen PC, Trentin PG, Rocco PR, Hogaboam CM, Puri RK, Martins MA, Silva PM.

J Immunol. 2013 Nov 15;191(10):5220-9. doi: 10.4049/jimmunol.1203551. Epub 2013 Oct 16.

30.

Protection against type 1 diabetes upon Coxsackievirus B4 infection and iNKT-cell stimulation: role of suppressive macrophages.

Ghazarian L, Diana J, Beaudoin L, Larsson PG, Puri RK, van Rooijen N, Flodström-Tullberg M, Lehuen A.

Diabetes. 2013 Nov;62(11):3785-96. doi: 10.2337/db12-0958. Epub 2013 Jul 26.

31.

Immunomodulatory effects of interferons in malignancies.

Bekisz J, Sato Y, Johnson C, Husain SR, Puri RK, Zoon KC.

J Interferon Cytokine Res. 2013 Apr;33(4):154-61. doi: 10.1089/jir.2012.0167. Review.

32.

Globin gene expression in correlation with G protein-related genes during erythroid differentiation.

Čokić VP, Smith RD, Biancotto A, Noguchi CT, Puri RK, Schechter AN.

BMC Genomics. 2013 Feb 20;14:116. doi: 10.1186/1471-2164-14-116.

33.

Targeting of interleukin-13 receptor α2 for treatment of head and neck squamous cell carcinoma induced by conditional deletion of TGF-β and PTEN signaling.

Hall B, Nakashima H, Sun ZJ, Sato Y, Bian Y, Husain SR, Puri RK, Kulkarni AB.

J Transl Med. 2013 Feb 19;11:45. doi: 10.1186/1479-5876-11-45.

34.

Differentially expressed genes and pathways induced by organophosphates in human neuroblastoma cells.

Li T, Zhao H, Hung GC, Han J, Tsai S, Li B, Zhang J, Puri RK, Lo SC.

Exp Biol Med (Maywood). 2012 Dec;237(12):1413-23. doi: 10.1258/ebm.2012.012178.

PMID:
23354400
35.

Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation.

Vatsan RS, Bross PF, Liu K, Theoret M, De Claro AR, Lu J, Helms W, Niland B, Husain SR, Puri RK.

J Immunother Cancer. 2013 May 29;1:5. doi: 10.1186/2051-1426-1-5. eCollection 2013. Review.

36.

Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling.

Castiello L, Sabatino M, Zhao Y, Tumaini B, Ren J, Ping J, Wang E, Wood LV, Marincola FM, Puri RK, Stroncek DF.

Mol Ther. 2013 Feb;21(2):476-84. doi: 10.1038/mt.2012.89. Epub 2012 Nov 13. Erratum in: Mol Ther. 2013 Feb;21(2):495.

37.

The tumor suppressor Caliban regulates DNA damage-induced apoptosis through p53-dependent and -independent activity.

Wang Y, Wang Z, Joshi BH, Puri RK, Stultz B, Yuan Q, Bai Y, Zhou P, Yuan Z, Hursh DA, Bi X.

Oncogene. 2013 Aug 15;32(33):3857-66. doi: 10.1038/onc.2012.395. Epub 2012 Sep 10.

PMID:
22964637
38.

Bioreactor environment-sensitive sentinel genes as novel metrics for cell culture scale-down comparability.

Kondragunta B, Joshi BH, Han J, Brorson KA, Puri RK, Moreira AR, Rao G.

Biotechnol Prog. 2012 Sep-Oct;28(5):1138-51. doi: 10.1002/btpr.1606. Epub 2012 Sep 18.

PMID:
22848039
39.

Genomic analysis of a hybridoma batch cell culture metabolic status in a standard laboratory 5 L bioreactor.

Kondragunta B, Han J, Joshi BH, Brorson KA, Puri RK, Uplekar S, Moreira AR, Rao G.

Biotechnol Prog. 2012 Sep-Oct;28(5):1126-37. doi: 10.1002/btpr.1605. Epub 2012 Sep 18.

PMID:
22837152
40.

JAK-STAT and AKT pathway-coupled genes in erythroid progenitor cells through ontogeny.

Cokic VP, Bhattacharya B, Beleslin-Cokic BB, Noguchi CT, Puri RK, Schechter AN.

J Transl Med. 2012 Jun 7;10:116. doi: 10.1186/1479-5876-10-116.

41.

Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.

Ou W, Marino MP, Suzuki A, Joshi B, Husain SR, Maisner A, Galanis E, Puri RK, Reiser J.

Hum Gene Ther Methods. 2012 Apr;23(2):137-47. doi: 10.1089/hgtb.2012.054. Epub 2012 May 21.

42.

Cysteamine suppresses invasion, metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer.

Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, Puri RK.

PLoS One. 2012;7(4):e34437. doi: 10.1371/journal.pone.0034437. Epub 2012 Apr 20.

43.

IL-13 receptor-directed cancer vaccines and immunotherapy.

Nakashima H, Husain SR, Puri RK.

Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28. Review.

PMID:
22512637
44.

Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.

Nakashima H, Miyake K, Clark CR, Bekisz J, Finbloom J, Husain SR, Baron S, Puri RK, Zoon KC.

Cancer Immunol Immunother. 2012 Jul;61(7):1081-92. doi: 10.1007/s00262-011-1152-x. Epub 2011 Dec 13.

45.

Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy.

Yang L, Horibe T, Kohno M, Haramoto M, Ohara K, Puri RK, Kawakami K.

Mol Cancer Ther. 2012 Jan;11(1):235-43. doi: 10.1158/1535-7163.MCT-11-0363. Epub 2011 Nov 14.

46.

A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.

Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK.

J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.

47.

IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.

Fujisawa T, Joshi BH, Puri RK.

Int J Cancer. 2012 Jul 15;131(2):344-56. doi: 10.1002/ijc.26366. Epub 2011 Sep 16.

48.

USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.

Russell SM, Lechner MG, Gong L, Megiel C, Liebertz DJ, Masood R, Correa AJ, Han J, Puri RK, Sinha UK, Epstein AL.

Oral Oncol. 2011 Sep;47(9):810-7. doi: 10.1016/j.oraloncology.2011.05.015. Epub 2011 Jun 29.

49.
50.

Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.

Nakashima H, Fujisawa T, Husain SR, Puri RK.

J Transl Med. 2010 Nov 10;8:116. doi: 10.1186/1479-5876-8-116.

Supplemental Content

Support Center